GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,629.00
Bid: 1,629.00
Ask: 1,629.50
Change: -11.00 (-0.67%)
Spread: 0.50 (0.031%)
Open: 1,633.00
High: 1,641.00
Low: 1,611.00
Prev. Close: 1,640.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European shares end fifth week higher on rate-cut optimism

Fri, 15th Dec 2023 17:08

Barclays sees first ECB rate cut in April

*

Villeroy: Next ECB move should be a cut; 'enjoy' the plateau

*

Sweden's Sectra tops STOXX 600 after Q2 report

*

Symrise slides on EBITDA margin outlook cut

Dec 15 (Reuters) -

European shares inched up on the final day of a week marked by major central bank policy decisions, in which the U.S. Federal Reserve set the tone for market expectations about interest rate cuts being on the horizon.

The pan-European STOXX 600 edged 0.1% higher on Friday, posting its fifth straight weekly advance and recording its longest weekly winning streak since April.

The German benchmark DAX was flat, while France's CAC-40 climbed 0.3% after both hit record highs on Thursday.

For the week, rate-sensitive real estate stocks were the top gainers, while the telecommunication sector took the worst hit.

On the policy front, the Fed stood out, signalling lower borrowing costs in 2024, while the European Central Bank held rates steady, pushing back against rate-cut bets on Thursday.

"Our economists see... the hawkish tilt of (Thursday's ECB meeting) as reducing the risk of the ECB cutting as soon as March, but retain their view of rate cuts starting in April with 150 bps of cuts by the end of next year," Deutsche Bank said in a note.

Barclays forecast a 25-basis-point ECB rate cut in April and consecutive cuts in each policy meeting until January 2025.

Meanwhile, ECB policymaker Francois Villeroy de Galhau said although the ECB's next move should be lowering rates, it should first "enjoy the view" for a while.

Economic concerns were underscored by weak data showing Germany's economic downturn worsened this month, pointing to a recession in Europe's biggest economy at the year-end, and French business activity declined faster than expected in December.

Weakness in the healthcare sector weighed for the day, with UK-based

GSK

slipping 2.9% after EU regulator pulled the plug on company's blood cancer drug.

Swedish technology firm Sectra jumped 8.3% to the top of STOXX 600 following second-quarter results.

Stockholm-listed receipts of Millicom gained 2.7% after the telecom group raised its target and launched a share buyback program.

EQT rose 4.3% after J.P. Morgan upgraded the Swedish private equity firm to "neutral" from "underweight".

Symrise lost 7.6% after the German flavour and fragrance maker cut its full-year EBITDA margin guidance.

Campari shed 2.9% after the Italian spirits group announced its biggest-ever acquisition to buy French cognac house Courvoisier for $1.2 billion. (Reporting by Ankika Biswas and Bansari Mayur Kamdar in Bengaluru; Editing by Janane Venkatraman and Andrew Heavens)

More News
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
3 Jun 2024 17:20

European shares kick-off June on a high note in anticipation of ECB rate cut

GSK tumbles as Zantac lawsuits allowed to proceed

*

Read more
3 Jun 2024 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
3 Jun 2024 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
3 Jun 2024 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
3 Jun 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
3 Jun 2024 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
3 Jun 2024 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
3 Jun 2024 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
3 Jun 2024 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.